Baumeler Alfred 4

4 · Synergy CHC Corp. · Filed Jul 1, 2026

AI-generated summary of this filing

Updated Jul 1, 2026

Synergy CHC (SNYR) President Alfred Baumeler Receives Modified Option Grant

What Happened

Alfred Baumeler, President and a director of Synergy CHC Corp. (SNYR), had a 150,000-share option cancelled and was granted a new 150,000-share option on June 29, 2026. Both entries are reported as derivative transactions (no per-share price shown in the filing).
The filing notes the change reflects a reduction in the exercise price of the original option, which the company treats as a material modification — effectively cancelling the original option and issuing a replacement option with the same vesting schedule.

Key Details

Transaction date: June 29, 2026; Form 4 filed July 1, 2026 (covering the June 29 transactions).
Reported transactions: Disposition to issuer (cancellation) of 150,000 derivative shares and simultaneous acquisition (new grant) of 150,000 derivative shares. Price: N/A (not reported).
Vesting: One-third vests on the first anniversary of the original grant date (Sept 18, 2025); remaining two-thirds vest in equal monthly installments over the following 24 months (see footnote). The new option vests as if granted on the original grant date.
Expiration: The new option expires on the five-year anniversary of the original grant date (Sept 18, 2030).
Shares owned after transaction: Not specified in the Form 4.
Footnotes: F1 describes the vesting schedule. F2 explains the exercise-price reduction constitutes a material modification and the original option is deemed cancelled and replaced.
Filing timeliness: Form 4 was filed on July 1, 2026 for transactions dated June 29, 2026 (no late-filing flag reported).

Context

This filing reflects an option modification (derivative transaction), not an open-market buy or sell of stock. Such modifications can change the option's economics (here, a reduced exercise price), but do not by themselves indicate buying or selling of underlying shares.
For retail investors, option grants/modifications by insiders are informative about compensation and retention, but they don't directly imply immediate market purchases or sales.

Form 4

Period: 2026-06-29

DirectorPresident

Transactions

Award
Stock Option (right to buy)
[F2][F1]
2026-06-29+150,000→ 150,000 total
Exercise: $0.21Exp: 2030-09-18→ Common Stock, par value $0.00001 per share (150,000 underlying)
Disposition to Issuer
Stock Option (right to buy)
[F2][F1]
2026-06-29−150,000→ 0 total
Exercise: $2.38Exp: 2030-09-18→ Common Stock, par value $0.00001 per share (150,000 underlying)

Footnotes (2)

[F1]One-third (1/3) of this option grant (the "Original Option") vests on the first anniversary of September 18, 2025 (the "Original Grant Date"), and the remaining two-thirds (2/3) vest in equal monthly installments over the twenty-four (24) months thereafter, in each case subject to the reporting person's continued service with the Company.
[F2]The reduction in the exercise price of the Original Option constitutes a material modification and is deemed, for purposes of Section 16, to involve a cancellation of the Original Option and the grant of a new option in its place. The new option vests on the same schedule as the Original Option, as if it had been granted on the Original Grant Date, and expires on the five-year anniversary of the Original Grant Date.

Signature

/s/ Nelson Mullins Riley & Scarborough LLP, Attorney-in-Fact|2026-07-01

1 file